Access to Innovative Neurological Drugs in Europe: Alignment of Health Technology Assessments Among Three European Countries

Even for products centrally approved, each European country is responsible for national market access after European Medicines Agency (EMA) approval. This step can result in inequalities in terms of access, due to different opinions about the therapeutic value assessed by Health Technology Assessmen...

Descripción completa

Detalles Bibliográficos
Autores principales: Gozzo, Lucia, Romano, Giovanni Luca, Brancati, Serena, Cicciù, Marco, Fiorillo, Luca, Longo, Laura, Vitale, Daniela Cristina, Drago, Filippo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854989/
https://www.ncbi.nlm.nih.gov/pubmed/35185551
http://dx.doi.org/10.3389/fphar.2021.823199

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8854989/
https://www.ncbi.nlm.nih.gov/pubmed/35185551
http://dx.doi.org/10.3389/fphar.2021.823199

Ejemplares similares